Here in one handy post are the various criticisms I’ve made of ATAGI’s performance:
- ATAGI and the law of large numbers
- How ATAGI really screwed up
- ATAGI, Astra Zeneca and risk (how not to do risk assessments)
Really quite depressing that a blue ribbon committee such as this couldn’t see it’s way to getting expert advice on the one thing it was there to provide expert advice on, risk.